LEADER 01808nam  2200469   450 
001 9910703041403321
005 20221105123148.0
035   $a(CKB)3450000000002396
035   $a(NjHacI)993450000000002396
035   $a(OCoLC)741122408
035   $a(EXLCZ)993450000000002396
100   $a20221105d2010      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAssessment of thiopurine methyltransferase activity in patients prescribed azathioprine or other thiopurine-based drugs /$fRonald A. Booth [and seventeen others]
210  1$aRockville, Maryland :$cAgency for Healthcare Research and Quality (US),$d[2010]
210  4$dİ2010
215   $a1 online resource (288 pages) $cillustrations
225 1 $aEvidence Reports/Technology Assessments
300   $aTitle from title screen (viewed on July 12, 2011).
300   $a"EPC Director: David Moher, Ph.D."
300   $a"Investigators: Ronald A. Booth, Ph.D. ... [et al.]."
300   $a"December 2010."
320   $aIncludes bibliographical references.
410  0$aEvidence report/technology assessment.
606   $aAutoimmune diseases
615  0$aAutoimmune diseases.
676   $a616.978
700   $aBooth$b Ronald A.
701   $aMoher$b David$f1957-$01194244
701   $aBooth$b Ronald A$01351417
712 02$aUnited States.$bAgency for Healthcare Research and Quality.
712 02$aUniversity of Ottawa Evidence-based Practice Center.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910703041403321
996   $aAssessment of thiopurine methyltransferase activity in patients prescribed azathioprine or other thiopurine-based drugs$93471071
997   $aUNINA